Income StatementBalance SheetCash FlowSegments
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals Business Segments

Business, geographic, and product segment breakdowns

Alnylam Pharmaceuticals generates $4.3B in annual revenue across 2 key segments: Vutrisiran ($85.2M), and Zilebesrian ($7.0M). The company-wide operating margin is 17.54%. Based on the Q1 2026 filing.

Vutrisiran (TTM)$85.2MZilebesrian (TTM)$7.0M
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$39.2B
P/E Ratio72.83
ROE71.66%

Products & Services

Maximum funding

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
HELIOS-B Phase 3 Clinical Trial————$70.0M$70.0M
ALN-AGT Phase 2 Clinical Trial————$26.0M$26.0M
ALN-AGT Phase 3 Clinical Trial———$18.0M$6.0M$12.0M

Transaction price

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
License———$1.7B$1.7B$1.7B
Roche Development Services Obligation$937.5M$937.5M$1.1B—$1.1B$1.1B
Roche License Obligation$375.0M$375.0M$675.0M—$675.0M$675.0M
Research Services Obligation——$100.5M$100.5M$100.5M$100.5M
Roche Technology Transfer Obligation$2.0M$2.0M$2.0M—$2.0M$2.0M

Effective interest rate (as percent)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Vutrisiran————46.0%49.0%
Zilebesrian————32.0%32.0%

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Vutrisiran—$19.4M$19.4M$19.4M$19.4M$30.1M
Zilebesrian—$5.3M$5.3M$5.3M$5.3M$5.3M

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Vutrisiran$190.1M———$194.2M$187.9M
Zilebesrian$25.3M———$17.0M$19.6M

Interest Expense

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Vutrisiran—$20.4M$20.4M$20.4M$20.4M$23.9M
Zilebesrian—$1.7M$1.7M$1.7M$1.7M$1.8M

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Zilebesrian—$1.5M$1.5M$1.5M$1.5M$6.0M